Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Enzyme Suppletion in Exocrine Pancreatic Dysfunction (SAPES)

This study has been completed.
Axcan Pharma
Information provided by (Responsible Party):
Edmee Sikkens, Foundation for Liver Research Identifier:
First received: September 1, 2011
Last updated: February 11, 2013
Last verified: February 2013
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: February 2013
  Primary Completion Date: February 2013 (Final data collection date for primary outcome measure)